1. Home
  2. EDRY vs MURA Comparison

EDRY vs MURA Comparison

Compare EDRY & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EuroDry Ltd.

EDRY

EuroDry Ltd.

HOLD

Current Price

$13.06

Market Cap

36.9M

ML Signal

HOLD

Logo Mural Oncology plc

MURA

Mural Oncology plc

HOLD

Current Price

$2.03

Market Cap

36.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDRY
MURA
Founded
2018
2013
Country
Greece
Ireland
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
36.9M
36.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EDRY
MURA
Price
$13.06
$2.03
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
3.2K
224.8K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$49,384,447.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$21.94
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.60
$0.95
52 Week High
$16.14
$4.74

Technical Indicators

Market Signals
Indicator
EDRY
MURA
Relative Strength Index (RSI) 49.39 40.40
Support Level $12.94 $2.06
Resistance Level $13.75 $2.10
Average True Range (ATR) 0.27 0.01
MACD -0.06 -0.01
Stochastic Oscillator 45.34 25.00

Price Performance

Historical Comparison
EDRY
MURA

About EDRY EuroDry Ltd.

EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Share on Social Networks: